Bayer gastrointestinal tumour drug receives FDA orphan drug designation
Bayer had initiated patient enrolment for a randomised, double-blind, placebo-controlled Phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.